top of page
Create Your First Project
Start adding your projects to your portfolio. Click on "Manage Projects" to get started
Zymeworks’ lead product candidate, zanidatamab, is a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric™ platform. Zanidatamab is currently being evaluated as a best-in-class treatment for patients with HER2-expressing cancers, including biliary tract, gastroesophageal adenocarcinomas, breast, and other tumor types.
Entry Price: $7.47
Date
November 2022
Zymeworks
bottom of page